Dr. Mody on Progress Made With Y-90 in Hepatocellular Carcinoma
Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.
Dr. Mody on the Unique Delivery Approach for Y-90 in HCC
Kabir Mody, MD, discusses the unique approach used to deliver Y-90 glass microspheres to patients with unresectable hepatocellular carcinoma.
Dr. Mody Highlights Treatment Advances in HCC
Kabir Mody, assistant professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, highlights the recent treatment advances for patients with hepatocellular carcinoma.
Dr. Mody Discusses Treatment Options for HCC
Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses treatment options for patients with hepatocellular carcinoma.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512